デング熱ワクチンの世界市場の機会と戦略（～2034年）

世界のデング熱ワクチンの市場規模は、2019年に260万米ドルであり、2024年まで174.00%を超えるCAGRで成長しました。

デング熱罹患率の上昇

デング熱罹患率の上昇は、過去の期間中のデング熱ワクチン市場の成長を支えました。デング熱患者の急増に伴い、政府、医療組織、個人は効果的な予防戦略を優先しています。ワクチン接種は、特に蚊が媒介する疾病が発生しやすい地域において、デング熱発生を管理する上で極めて重要なソリューションとして浮上しています。このような大流行は、入院、医学的ケア、労働生産性の低下により、多額の医療費用と経済的混乱をもたらすことが多いです。そのため、ステークホルダーはワクチン接種がこの疾患の全体的な影響を軽減する費用効率の高いアプローチであると認識しています。例えば、スイスに本部を置く政府間機関である世界保健機関（WHO）によると、2024年5月、南北アメリカ地域ではデング熱の罹患者数が700万人を突破し、2023年に記録された460万人から大幅に増加しました。したがって、デング熱罹患率の上昇がデング熱ワクチン市場の成長を促進しました。

当レポートでは、世界のデング熱ワクチン市場について調査分析し、市場の特徴、主な市場動向、市場規模と成長予測、競合情勢などの情報を提供しています。

目次

第1章 エグゼクティブサマリー

• デング熱ワクチン - 市場の魅力とマクロ経済情勢

第2章 目次

第3章 表のリスト

第4章 図表のリスト

第5章 レポートの構成

第6章 市場の特徴

• 一般的な市場の定義
• サマリー
• デング熱ワクチン市場の定義とセグメンテーション
• 市場のセグメンテーション：タイプ別
  • 生ワクチン
  • 不活化ワクチン
  • サブユニットワクチン
  • 核酸ワクチン
• 市場のセグメンテーション：投与経路別
  • 経口
  • 非経口
  • その他の治療
• 市場のセグメンテーション：エンドユーザー別
  • 病院
  • 診療所
  • 政府機関
  • 非政府組織
  • その他のエンドユーザー

第7章 主な市場動向

• デング熱感染の早期発見に向けた診断キットの進歩
• 世界のデング熱罹患率の増加に対処する新たなデング熱治療ソリューションへの投資
• デング熱ワクチン市場におけるイノベーションを推進する戦略的パートナーシップ

第8章 デング熱ワクチン市場 - マクロ経済シナリオ

• デング熱ワクチン市場に対するCOVID-19の影響
• デング熱ワクチン市場に対するウクライナ戦争の影響
• デング熱ワクチン市場に対する高インフレの影響

第9章 世界の市場規模と成長

• 市場規模
• 市場成長の実績（2019年～2024年）
  • 市場促進要因（2019年～2024年）
  • 市場抑制要因（2019年～2024年）
• 市場成長の予測（2024年～2029年・2034年）
  • 市場促進要因（2024年～2029年）
  • 市場抑制要因（2024年～2029年）

第10章 世界のデング熱ワクチン市場のセグメンテーション

• 世界のデング熱ワクチン市場：タイプ別、実績と予測（2019年～2024年・2029年・2034年）
• 世界のデング熱ワクチン市場：投与経路別、実績と予測（2019年～2024年・2029年・2034年）
• 世界のデング熱ワクチン市場：エンドユーザー別、実績と予測（2019年～2024年・2029年・2034年）

第11章 デング熱ワクチン市場、地域と国の分析

• 世界のデング熱ワクチン市場：地域別、実績と予測（2019年～2024年・2029年・2034年）
• 世界のデング熱ワクチン市場：国別、実績と予測（2019年～2024年・2029年・2034年）

第12章 アジア太平洋市場

第13章 西欧市場

第14章 東欧市場

第15章 北米市場

第16章 南米市場

第17章 中東市場

第18章 アフリカ市場

第19章 競合情勢と企業プロファイル

• 企業プロファイル
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Panacea Biotec Ltd

第20章 その他の主要企業と革新的企業

• Codagenix Inc
• Serum Institute of India
• Inovio Pharmaceuticals Inc
• Novavax, Inc
• Medigen Vaccine Biologics Corporation
• The International Vaccine Institute (ivi.int)
• Bharat Biotech International Limited
• Sinovac Biotech Ltd
• SABIN Vaccine Institute Inc
• VabioTech
• BioNet-Asia Co. Ltd
• Hilleman Laboratories Pvt. Ltd
• Biological E. Limited
• K.M. Biologics
• Emergex

第21章 競合ベンチマーキング

第22章 競合ダッシュボード

第23章 機会と戦略

• 世界のデング熱ワクチン市場 - もっとも新たな機会を提供する国（2029年）
• 世界のデング熱ワクチン市場 - もっとも新たな機会を提供するセグメント（2029年）
• 世界のデング熱ワクチン市場 - 成長戦略（2029年）
  • 市場動向に基づく戦略
  • 競合の戦略

第24章 デング熱ワクチン市場：結論と提言

• 結論
• 提言
  • 製品
  • 流通
  • 価格
  • プロモーション
  • 人々

第25章 付録

A dengue vaccine is a biological preparation designed to protect individuals against dengue fever, a viral infection caused by the dengue virus (DENV). This virus is transmitted primarily through the bite of infected Aedes mosquitoes, especially Aedes aegypti. Dengue fever causes a range of symptoms, from mild flu-like illness to severe complications such as dengue hemorrhagic fever and dengue shock syndrome, which can be life-threatening.

The dengue vaccine market consists of sales by entities (organizations, sole traders and partnerships) of dengue vaccine that focuses on providing solutions to mitigate the severe health risks associated with the disease, which can range from flu-like symptoms to life-threatening complications like dengue hemorrhagic fever and dengue shock syndrome.

The global dengue vaccine market was valued at $2.60 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 174.00%.

Rising Dengue Incidence

The rising dengue incidence supported the growth of the dengue vaccine market during the historic period. With the surge in dengue cases, governments, healthcare organizations and individuals are prioritizing effective prevention strategies. Vaccination emerges as a pivotal solution in managing dengue outbreaks, particularly in regions prone to mosquito-borne diseases. These outbreaks often result in substantial healthcare expenses and economic disruptions, driven by hospitalizations, medical care and decreased workforce productivity. Consequently, stakeholders recognize vaccination as a cost-efficient approach to mitigating the overall impact of the disease. For instance, in May 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in the American region, dengue cases surpassed 7 million in April 2024, a significant increase from the 4.6 million cases recorded in 2023. Therefore, the rising dengue incidence drove the growth of the dengue vaccine market.

Investment In Novel Dengue Treatment Solutions To Address Rising Global Incidence

Major companies operating in the dengue vaccine market are focusing on strategic investments to expand their product portfolios, enhance vaccine efficacy and improve global access. Strategic investments drive the growth of the dengue vaccine market by boosting funding for research and development, allowing manufacturers to develop more efficient and advanced vaccines. For instance, in October 2023, Codagenix Inc., a US-based clinical-stage biotechnology company focused on developing vaccines received an award of $5.88 million from U.S. Department of Defense (DoD) to further develop its dengue vaccine candidate, CodaVax-DENV. The funding will support the initiation of a first-in-human Phase 1 trial, which will evaluate the vaccine's safety and immunogenicity. This initiative aligns with a broader strategy to combat dengue fever, a significant health threat, particularly for military personnel deployed in endemic regions.

The global dengue vaccine market is highly concentrated, with few players operating in the market. The top ten competitors in the market made up to 100.0% of the total market in 2023.

Dengue Vaccine Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global dengue vaccine market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for dengue vaccine? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The dengue vaccine market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider dengue vaccine market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by route of administration and by end user.
• Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the dengue vaccine market.
• Global Market Size And Growth - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
• Regional And Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
• Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by route of administration and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
• Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
• Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
• Competitive Dashboard- Briefs on competitive dashboard of major players.
• Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for dengue vaccine market providers in terms of product/service offerings geographic expansion, marketing strategies and target groups next five years.
• Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Type: Live Attenuated Vaccine; Inactivated Vaccine; Subunit Vaccine; Nucleic Acid-Based Vaccine
• 2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 3) By End User: Hospitals; Clinics; Government Institutes; Non-Governmental Organizations; Other End-Users
• Companies Mentioned: Takeda Pharmaceutical Company Limited; Sanofi SA; GlaxoSmithKline plc; Merck & Co. Inc.; Panacea Biotec Ltd.
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; dengue vaccine indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Dengue Vaccine - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Dengue Vaccine Market Definition And Segmentations
• 6.4 Market Segmentation By Type
  • 6.4.1 Live Attenuated Vaccine
  • 6.4.2 Inactivated Vaccine
  • 6.4.3 Subunit Vaccine
  • 6.4.4 Nucleic Acid-Based Vaccine
• 6.5 Market Segmentation By Route of Administration
  • 6.5.1 Oral
  • 6.5.2 Parenteral
  • 6.5.3 Other Treatment
• 6.6 Market Segmentation By End User
  • 6.6.1 Hospital
  • 6.6.2 Clinic
  • 6.6.3 Government Institutes
  • 6.6.4 Non-Governmental Organizations
  • 6.6.5 Other End-Users

7 Major Market Trends

• 7.1 Advancements In Diagnostic Kits For Early Detection Of Dengue Infections
• 7.2 Investment In Novel Dengue Treatment Solutions To Address Rising Global Incidence
• 7.3 Strategic Partnerships Driving Innovation In The Dengue Vaccine Market

8 Dengue Vaccine Market - Macro Economic Scenario

• 8.1 COVID-19 Impact On The Dengue Vaccine Market
• 8.2 Impact Of The War In Ukraine On The Dengue Vaccine Market
• 8.3 Impact Of High Inflation On The Dengue Vaccine Market

9 Global Market Size and Growth

• 9.1 Market Size
• 9.2 Historic Market Growth, 2019 - 2024, Value ($ Million)
  • 9.2.1 Market Drivers 2019 - 2024
  • 9.2.2 Market Restraints 2019 - 2024
• 9.3 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
  • 9.3.1 Market Drivers 2024 - 2029
  • 9.3.2 Market Restraints 2024 - 2029

10 Global Dengue Vaccine Market Segmentation

• 10.1 Global Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.2 Global Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.3 Global Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Dengue Vaccine Market, Regional and Country Analysis

• 11.1 Global Dengue Vaccine Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.2 Global Dengue Vaccine Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Asia-Pacific Market

• 12.1 Summary
• 12.2 Market Overview
  • 12.2.1 Region Information
  • 12.2.2 Market Information
  • 12.2.3 Background Information
  • 12.2.4 Government Initiatives
  • 12.2.5 Regulations
  • 12.2.6 Regulatory Bodies
  • 12.2.7 Major Associations
  • 12.2.8 Taxes Levied
  • 12.2.9 Corporate Tax Structure
  • 12.2.10 Investments
  • 12.2.11 Major Companies
• 12.3 Asia-Pacific Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.4 Asia-Pacific Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.5 Asia-Pacific Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.6 Asia-Pacific Dengue Vaccine Market: Country Analysis
• 12.7 China Market
• 12.8 Market Overview
  • 12.8.1 Country Information
  • 12.8.2 Market Information
  • 12.8.3 Background Information
  • 12.8.4 Government Initiatives
  • 12.8.5 Regulations
  • 12.8.6 Regulatory Bodies
  • 12.8.7 Major Associations
  • 12.8.8 Taxes Levied
  • 12.8.9 Corporate Tax Structure
  • 12.8.10 Major Companies
• 12.9 China Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.10 China Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.11 China Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.12 India Market
• 12.13 India Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.14 India Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.15 India Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.16 Japan Market
• 12.17 Japan Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.18 Japan Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.19 Japan Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.20 Australia Market
• 12.21 Australia Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.22 Australia Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.23 Australia Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.24 Indonesia Market
• 12.25 Indonesia Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.26 Indonesia Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.27 Indonesia Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.28 South Korea Market
• 12.29 South Korea Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.30 South Korea Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.31 South Korea Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Western Europe Market

• 13.1 Summary
• 13.2 Market Overview
  • 13.2.1 Region Information
  • 13.2.2 Market Information
  • 13.2.3 Background Information
  • 13.2.4 Government Initiatives
  • 13.2.5 Regulations
  • 13.2.6 Regulatory Bodies
  • 13.2.7 Major Associations
  • 13.2.8 Taxes Levied
  • 13.2.9 Corporate tax structure
  • 13.2.10 Investments
  • 13.2.11 Major Companies
• 13.3 Western Europe Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.4 Western Europe Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.5 Western Europe Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.6 Western Europe Dengue Vaccine Market: Country Analysis
• 13.7 UK Market
• 13.8 UK Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.9 UK Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.10 UK Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.11 Germany Market
• 13.12 Germany Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.13 Germany Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.14 Germany Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.15 France Market
• 13.16 France Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.17 France Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.18 France Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.19 Italy Market
• 13.20 Italy Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.21 Italy Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.22 Italy Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.23 Spain Market
• 13.24 Spain Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.25 Spain Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.26 Spain Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 Eastern Europe Market

• 14.1 Summary
• 14.2 Market Overview
  • 14.2.1 Region Information
  • 14.2.2 Market Information
  • 14.2.3 Background Information
  • 14.2.4 Regulations
  • 14.2.5 Regulatory Bodies
  • 14.2.6 Major Associations
  • 14.2.7 Taxes Levied
  • 14.2.8 Corporate Tax Structure
  • 14.2.9 Major companies
• 14.3 Eastern Europe Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.4 Eastern Europe Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.5 Eastern Europe Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.6 Eastern Europe Dengue Vaccine Market: Country Analysis
• 14.7 Russia Market
• 14.8 Russia Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.9 Russia Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.10 Russia Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 North America Market

• 15.1 Summary
• 15.2 Market Overview
  • 15.2.1 Region Information
  • 15.2.2 Market Information
  • 15.2.3 Background Information
  • 15.2.4 Government Initiatives
  • 15.2.5 Regulations
  • 15.2.6 Regulatory Bodies
  • 15.2.7 Major Associations
  • 15.2.8 Taxes Levied
  • 15.2.9 Corporate Tax Structure
  • 15.2.10 Investments
  • 15.2.11 Major Companies
• 15.3 North America Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.4 North America Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.5 North America Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.6 North America Dengue Vaccine Market: Country Analysis
• 15.7 USA Market
• 15.8 Summary
• 15.9 Market Overview
  • 15.9.1 Country Information
  • 15.9.2 Market Information
  • 15.9.3 Background Information
  • 15.9.4 Government Initiatives
  • 15.9.5 Regulations
  • 15.9.6 Regulatory Bodies
  • 15.9.7 Major Associations
  • 15.9.8 Taxes Levied
  • 15.9.9 Corporate Tax Structure
  • 15.9.10 Investments
  • 15.9.11 Major Companies
• 15.10 USA Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.11 USA Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.12 USA Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.13 Canada Market
• 15.14 Canada Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.15 Canada Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.16 Canada Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 South America Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate Tax Structure
  • 16.2.10 Investments
  • 16.2.11 Major Companies
• 16.3 South America Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.4 South America Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.5 South America Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.6 South America Dengue Vaccine Market: Country Analysis
• 16.7 Brazil Market
• 16.8 Brazil Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.9 Brazil Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.10 Brazil Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Middle East Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Investments
  • 17.2.11 Major Companies
• 17.3 Middle East Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.4 Middle East Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.5 Middle East Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Africa Market

• 18.1 Market Overview
  • 18.1.1 Region Information
  • 18.1.2 Market Information
  • 18.1.3 Background Information
  • 18.1.4 Government Initiatives
  • 18.1.5 Regulations
  • 18.1.6 Regulatory Bodies
  • 18.1.7 Major Associations
  • 18.1.8 Taxes Levied
  • 18.1.9 Corporate Tax Structure
  • 18.1.10 Major Companies
• 18.2 Africa Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.3 Africa Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.4 Africa Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

19 Competitive Landscape and Company Profiles

• 19.1 Company Profiles
• 19.2 Takeda Pharmaceutical Company Limited
  • 19.2.1 Company Overview
  • 19.2.2 Products And Services
  • 19.2.3 Business Strategy
  • 19.2.4 Financial Overview
• 19.3 Sanofi S.A.
  • 19.3.1 Company Overview
  • 19.3.2 Products And Services
  • 19.3.3 Financial Overview
• 19.4 GlaxoSmithKline plc
  • 19.4.1 Company Overview
  • 19.4.2 Products And Services
  • 19.4.3 Business Strategy
  • 19.4.4 Financial Overview
• 19.5 Merck & Co., Inc.
  • 19.5.1 Company Overview
  • 19.5.2 Products And Services
  • 19.5.3 Business Strategy
  • 19.5.4 Financial Overview
• 19.6 Panacea Biotec Ltd
  • 19.6.1 Company Overview
  • 19.6.2 Products And Services
  • 19.6.3 Business Strategy
  • 19.6.4 Financial Overview

20 Other Major And Innovative Companies

• 20.1 Codagenix Inc
  • 20.1.1 Company Overview
  • 20.1.2 Products and Services
• 20.2 Serum Institute of India
  • 20.2.1 Company Overview
  • 20.2.2 Products And Services
• 20.3 Inovio Pharmaceuticals Inc
  • 20.3.1 Company Overview
  • 20.3.2 Products and Services
• 20.4 Novavax, Inc
  • 20.4.1 Company Overview
  • 20.4.2 Products And Services
• 20.5 Medigen Vaccine Biologics Corporation
  • 20.5.1 Company Overview
  • 20.5.2 Products and Services
• 20.6 The International Vaccine Institute (ivi.int)
  • 20.6.1 Company Overview
  • 20.6.2 Products and Services
• 20.7 Bharat Biotech International Limited
  • 20.7.1 Company Overview
  • 20.7.2 Products and Services
• 20.8 Sinovac Biotech Ltd
  • 20.8.1 Company Overview
  • 20.8.2 Products and Services
• 20.9 SABIN Vaccine Institute Inc
  • 20.9.1 Company Overview
  • 20.9.2 Products and Services
• 20.10 VabioTech
  • 20.10.1 Company Overview
  • 20.10.2 Products and Services
• 20.11 BioNet-Asia Co. Ltd
  • 20.11.1 Company Overview
  • 20.11.2 Products and Services
• 20.12 Hilleman Laboratories Pvt. Ltd
  • 20.12.1 Company Overview
  • 20.12.2 Products and Services
• 20.13 Biological E. Limited
  • 20.13.1 Company Overview
  • 20.13.2 Products and Services
• 20.14 K.M. Biologics
  • 20.14.1 Company Overview
  • 20.14.2 Products and Services
• 20.15 Emergex
  • 20.15.1 Company Overview
  • 20.15.2 Products and Services

21 Competitive Benchmarking

22 Competitive Dashboard

23 Opportunities And Strategies

• 23.1 Global Dengue Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 23.2 Global Dengue Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 23.3 Global Dengue Vaccine Market In 2029 - Growth Strategies
  • 23.3.1 Market Trend Based Strategies
  • 23.3.2 Competitor Strategies

24 Dengue Vaccine Market, Conclusions And Recommendations

• 24.1 Conclusions
• 24.2 Recommendations
  • 24.2.1 Product
  • 24.2.2 Place
  • 24.2.3 Price
  • 24.2.4 Promotion
  • 24.2.5 People

25 Appendix

• 25.1 Geographies Covered
• 25.2 Market Data Sources
• 25.3 Research Methodology
• 25.4 Currencies
• 25.5 The Business Research Company
• 25.6 Copyright and Disclaimer